Microclots are tiny, abnormal clumps of clotted blood protein that resist the body’s normal clot-dissolving machinery and can linger in circulation, potentially blocking the smallest blood vessels. They gained widespread attention during the COVID-19 pandemic, when researchers found them in unusually high numbers in people with Long COVID, but the science behind them stretches into other chronic inflammatory conditions as well. The topic sits at a fascinating and sometimes contentious intersection of clotting biology, infection science, and chronic disease, and the research is still rapidly evolving.
How Microclots Differ From Normal Blood Clots
Your body forms and dissolves tiny clots all the time. When you get a cut, fibrinogen (a protein dissolved in your blood) gets converted into fibrin, which weaves itself into a mesh that plugs the wound. Once the wound heals, enzymes chew through that mesh and clear it away. This cycle of clotting and dissolving is tightly balanced, and under normal circumstances, it works smoothly.
Microclots break that cycle. Researchers discovered several years ago that fibrinogen can sometimes clot into a structurally different form of fibrin, one that folds into dense, tightly packed sheets rather than the normal loose mesh. This abnormal structure is called “amyloid” fibrin, borrowing the term from the misfolded protein clumps seen in diseases like Alzheimer’s. The key problem is that amyloid fibrin resists the enzymes that normally dissolve clots. The result is clots that persist in the bloodstream long after they should have been cleared.1PubMed Central. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
These aren’t large clots like the ones that cause strokes or deep vein thrombosis. They’re microscopic, sometimes just a few hundred square micrometers in area. But their resistance to breakdown means they accumulate, and their small size lets them lodge in capillaries, the thinnest blood vessels where oxygen passes from blood into tissue.
What Triggers Their Formation
Normal clotting requires a specific trigger, usually tissue damage or a chemical signal from an injury. Microclot formation appears to be driven by inflammation and certain molecular provocateurs that push fibrinogen into its abnormal amyloid shape. Researchers have shown that bacterial cell wall fragments, inflammatory molecules like serum amyloid A (SAA), and viral proteins can all induce this misfolding in laboratory conditions. The SARS-CoV-2 spike protein is one such trigger, and its amyloid-forming potential appears to be amplified in the presence of bacterial toxins or other inflammatory molecules.2Cell Death & Disease. Surface cues shape procoagulant properties of amyloidogenic microclots
This helps explain why microclots show up not only in COVID-19 but also in other conditions marked by chronic inflammation. The common thread isn’t one specific virus or bacterium; it’s the inflammatory environment that nudges fibrinogen toward that stubborn, misfolded state. Damage to the inner lining of blood vessels (the endothelium) also plays a role. During acute SARS-CoV-2 infection, for instance, the virus damages endothelial cells, which promotes widespread micro-scale clotting and disrupts the barriers between blood and tissues across multiple organs.3PubMed Central. Damage to endothelial barriers and its contribution to long COVID
What Gets Trapped Inside
Microclots aren’t just tangles of misfolded fibrin. When researchers dissolved these clots using strong chemical methods and analyzed what came out, they found a cargo of trapped molecules. Among the most notable were alpha-2 antiplasmin, a protein that actively blocks the body’s clot-dissolving enzymes, along with various fibrinogen chains and serum amyloid A.4PubMed Central. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin The presence of antiplasmin inside the clots is especially relevant because it creates a kind of self-reinforcing trap: the very molecules that could dissolve the clot are being blocked by a protein trapped within it.
Broader proteomic analysis confirmed that these microclots entrap a substantial number of inflammatory molecules, including ones that may further inhibit clot breakdown.5PubMed Central. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system So the picture that emerges is not just of a clot that won’t dissolve, but of a clot that carries its own anti-dissolving toolkit and its own inflammatory payload. This may help explain why, once established, microclots seem to be so difficult for the body to clear on its own.
How Microclots May Cause Symptoms
The leading theory for why microclots matter clinically is straightforward: they block capillaries. Capillaries are so narrow that red blood cells pass through them one at a time. If even a small amyloid fibrin clot gets stuck in a capillary, oxygen can’t reach the tissue on the other side. Multiply that across thousands of capillaries, and you get patchy, widespread tissue oxygen starvation.
This capillary-level blockage is largely invisible to standard medical imaging. You won’t see microclots on a CT scan or a standard blood test, and conventional clotting panels often come back normal. But the oxygen deficit they cause is real. Research has outlined how disturbances in capillary flow can limit oxygen exchange in both the lungs and peripheral tissues, potentially explaining the breathlessness and fatigue that standard tests can’t account for.6PubMed Central. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation
In Long COVID specifically, researchers have proposed that fibrin amyloid microclots blocking capillaries, combined with hyperactivated platelets (platelets that are stuck in an overly sticky, clump-prone state), provide a plausible explanation for hallmark symptoms like crushing fatigue, brain fog, and exercise intolerance.7PubMed Central. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) When oxygen delivery is compromised at the capillary level, it would affect whichever organs rely most on a constant oxygen supply, which is to say the brain, the muscles, and the heart.
The Long COVID Connection
Long COVID is where microclot research exploded into public awareness. Studies using imaging flow cytometry have found that the total number of microclots in plasma is dramatically higher in people with Long COVID compared to healthy controls. One study reported a roughly 20-fold median difference in microclot counts, with the elevation statistically significant across every size range measured.8PubMed Central. Circulating Microclots Are Structurally Associated With Neutrophil Extracellular Traps and Their Amounts Are Elevated in Long COVID Patients That same study found that microclots were structurally associated with neutrophil extracellular traps, which are web-like structures released by immune cells during inflammation, adding another layer to the biology.
The disease pathway argument has been strengthened by the observation that the extent of microclot formation correlates with how virulent a given SARS-CoV-2 variant is. More aggressive variants produce more microclots, which is the kind of dose-response relationship that suggests microclots are part of the disease mechanism rather than a bystander effect.9Research and Practice in Thrombosis and Haemostasis. Fibrinaloid microclots in long COVID: assessing the actual evidence properly The persistent coagulation abnormalities in Long COVID, including endothelial inflammation, hyperactivated platelets, and ongoing microclot formation, have been described as a self-perpetuating cycle of thrombotic endothelialitis.10PubMed Central. Long COVID: pathophysiological factors and abnormalities of coagulation
Microclots Beyond COVID
While Long COVID brought microclots to mainstream attention, the phenomenon isn’t limited to one disease. Before the pandemic, amyloid fibrin clots had already been observed in conditions involving chronic inflammation, and post-pandemic research has extended the findings to other patient groups.
In myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), researchers found both hyperactivated platelets and substantial microclot formation. The area of plasma images containing microclots was commonly more than tenfold greater in people with ME/CFS than in healthy controls. Platelets showed pronounced hyperactivation, with spreading scores nearly three times higher than those of controls.11PubMed Central. The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) The overlap in microclot pathology between ME/CFS and Long COVID is striking, especially given the overlap in symptoms between the two conditions. Both feature profound fatigue, cognitive difficulties, and exercise intolerance, and the microclot findings suggest a possible shared mechanism of capillary-level oxygen deprivation.
Microclots have also been detected in plasma from people with Type 2 diabetes without the addition of any clotting agent, using the same fluorescent staining approach.12PubMed Central. Prevalence of readily detected amyloid blood clots in ‘unclotted’ Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report Type 2 diabetes is a condition defined by chronic low-grade inflammation and vascular complications, so the presence of amyloid fibrin clots fits the broader pattern of inflammation driving abnormal clot formation. How much these microclots contribute to the vascular problems in diabetes, as opposed to being a downstream marker of them, remains an open question.
How Microclots Are Detected
One reason microclots flew under the radar for so long is that they don’t show up on routine bloodwork. Standard clotting tests measure how long it takes blood to clot or how much of certain clotting factors are present, but they don’t look for the presence of pre-formed, misfolded fibrin clumps already sitting in the plasma.
The primary detection method has been fluorescence microscopy. Researchers take platelet-poor plasma (the liquid part of blood after cells and platelets have been removed), stain it with a dye called thioflavin T (or related “Amytracker” stains that bind to amyloid structures), and examine it under a fluorescence microscope. The microclots light up brightly against a dark background. This is effective for research, but it’s labor-intensive and not something a typical hospital lab can do at scale.
A more accessible method has been developed using flow cytometry, a technology already standard in pathology labs worldwide. Imaging flow cytometry combines the single-cell image capture of microscopy with the high-throughput speed of a flow cytometer, allowing researchers to count and measure microclots in large plasma samples quickly and with good accuracy.13PubMed Central. Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model Encouragingly, the researchers behind this work suggest that even conventional flow cytometers, without the imaging component, should be able to detect the fluorescent signal from microclots. If that holds true, it would bring microclot testing within reach of many existing clinical labs without requiring new equipment, a significant step toward making these measurements part of routine care.
Treatment Approaches and Why They’re Controversial
If microclots are causing symptoms by blocking capillaries and resisting normal clot breakdown, the logical treatment would be either to dissolve them or to physically remove them. Several approaches have been explored, but none has reached the point of established, guideline-backed therapy, and the debate around treatment is spirited.
Some clinicians have tried anticoagulant regimens, sometimes combining blood thinners with antiplatelet drugs, aiming to prevent new microclot formation and reduce platelet hyperactivation. However, experts in thrombosis have raised concerns about moving to widespread anticoagulant use without randomized controlled trials. The evidence for microclots playing a causal role in Long COVID symptoms is suggestive but not yet proven in the way clinical medicine demands, and anticoagulants carry real bleeding risks.14Heliyon. Uncertainties about the roles of anticoagulation and microclots in postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection Without trial data showing that the benefits outweigh the harms, recommending these treatments broadly is premature.
A more targeted approach involves extracorporeal blood filtration. One technique, known as H.E.L.P. apheresis (heparin-induced extracorporeal LDL/fibrinogen precipitation), passes blood through a machine that uses heparin to precipitate and remove fibrinogen and related clotting material. Proponents argue that it removes large amounts of fibrinogen, dissolves forming microthrombi without bleeding risk, and may even strip SARS-CoV-2 viral debris from circulation, since heparin binds the spike protein.15PubMed Central. The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19 The procedure is expensive, requires specialized equipment, and has been used primarily in small case series rather than large trials, so it remains experimental.
At the more experimental end of the spectrum, laboratory work has examined whether ultrasound combined with clot-dissolving enzymes could break apart amyloid microclots. One study tested combinations of enzymes (including nattokinase and lumbrokinase) with ultrasound-induced microbubbles. Interestingly, mechanical ultrasound forces alone were the dominant contributors to clot disruption at lower frequencies, while enzymatic treatment only added a modest boost at higher frequencies where ultrasound alone was less effective.16Springer Link / J Thromb Thrombolysis. Investigation of the synergistic effect of enzymatic and Ultrasound-Induced amyloid microclot degradation This is bench science, far from clinical application, but it illustrates both the difficulty of dissolving these clots and the creative approaches researchers are testing.
The Ongoing Scientific Debate
Microclot research is not universally accepted as settled science, and some of the disagreements matter for how you should interpret the findings. The central question that remains is whether microclots are a cause of symptoms or a marker of an underlying inflammatory process that itself causes the symptoms. The distinction is important: if microclots are merely a sign of inflammation rather than the thing directly causing harm, then treatments aimed at dissolving them might address a symptom of the problem without fixing the root cause.
Supporters of the causal hypothesis point to several lines of evidence. The correlation between variant virulence and microclot burden suggests the clots track with disease severity. The roles of fibrin amyloid microclots have also been linked to disseminated intravascular coagulation and mortality in intensive care patients, with substantial odds ratios reported.9Research and Practice in Thrombosis and Haemostasis. Fibrinaloid microclots in long COVID: assessing the actual evidence properly And the mechanism of capillary blockage leading to tissue hypoxia is biologically plausible for the symptoms seen.
Skeptics note that much of the foundational microclot work has come from a relatively small group of researchers, that sample sizes in many studies have been modest, and that the field urgently needs blinded, multi-center replication studies and, above all, randomized controlled trials of microclot-targeted treatments. Without those trials, it’s impossible to know whether reducing microclot burden actually makes patients feel better. The fact that standard coagulation markers often look normal in Long COVID patients also complicates the picture, since it suggests the problem isn’t a broad coagulation failure but something more localized and structurally unusual.
This tension between promising mechanistic evidence and the lack of definitive clinical trial data is where the field sits right now. The science is compelling enough that major research institutions are investigating microclots seriously, but it hasn’t yet crossed the threshold where treatment guidelines can be written with confidence.
Microclots and the Broader Picture of Post-Infectious Illness
Perhaps the most intriguing aspect of microclot research is what it might reveal beyond any single disease. The finding that amyloid fibrin clots appear in ME/CFS, Type 2 diabetes, and acute sepsis, not just COVID-19, points to a more general mechanism. Chronic inflammation, regardless of its source, may push fibrinogen toward its abnormal, clot-resistant form. If confirmed, this would mean microclots represent a shared pathway through which diverse inflammatory insults produce overlapping symptoms like fatigue, cognitive impairment, and exercise intolerance.
For patients with ME/CFS, a condition that has been chronically underfunded and often dismissed, the microclot findings have been especially meaningful. Demonstrating measurable, objective abnormalities in clotting and platelet behavior gives biological grounding to symptoms that patients have reported for decades. The tenfold difference in microclot burden between ME/CFS patients and healthy controls is not a subtle finding; it’s the kind of gap that demands explanation and follow-up.11PubMed Central. The Occurrence of Hyperactivated Platelets and Fibrinaloid Microclots in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Whether microclot testing eventually becomes a routine diagnostic tool depends on several things falling into place: larger validation studies confirming the findings across diverse populations, standardization of the staining and flow cytometry protocols, and clinical trials showing that acting on microclot results changes patient outcomes. The technology to detect microclots using equipment already present in hospital labs exists, and the biological story connecting microclots to symptoms is coherent. What’s still missing is the clinical evidence tying the detection to treatment and the treatment to recovery. That gap is where the most important research of the next few years will focus.